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In subjects with Type 1 (insulin-dependent) diabetes an indication of B cell insulin secretory capacity may be obtained by measuring serum C-peptide reactivity before and after an appropriate stimulus. Of the agents used, glucagon has been stated to be the most suitable [1] . A significant correlation between fasting and stimulated serum C-peptide reactivity has been observed [1, 2] and denied 2.5 [3] . To clarify these differences, we measured B cell secretory capacity in 16 subjects with Type 1 diabetes whose age at onset of disease was less than 40 years (group 1), 18 subjects with Type 1 diabetes whose age at onset of disease was 40 years or more (group 2) and 22 subjects with Type 2 (non-insulin dependent) diabetes whose age at onset of disease was 40 years or more (group 3). Serum C-peptide reactivity was measured [4] in the fasting state, and 3, 6 and 10 rain 2.0 after the end of a 3-rain IV infusion of 1 mg of glucagon. Only sub- . O Fasting serum C-peptide reactivity levels were plotted against 1= maximum serum C-peptide reactivity for the subjects in each group "~ ( betes whose age at onset of disease varied between 3-50 years and o 13-49 years, respectively. Eft et al. found a correlation between fasting and post-glucose serum C-peptide reactivity (r = 0.69) in ~ 1.0 Type 1 diabetic subjects whose age at onset of disease was w < 30 years [5] . Mirel et al. [3] failed to find a correlation between fasting and post-glucagon serum C-peptide reactivity in Type 1 diabetic subjects whose age at onset of disease was 5-19 years (for all I= -1 but one subject, range was 5-15 years). In group 1 subjects in this I~ ,m study, age at onset of disease ranged from 14-39 years, x 0.! These results confirm that there is a positive correlation between fasting serum C-peptide reactivity and B cell insulin secretory capacity in subjects with Type 1 diabetes. This correlation may not be present when the disease develops in childhood. The correlation between fasting serum C-peptide reactivity and B cell secretory capacity is also present in subjects with Type 2 diabetes. 
